I. Call to Order ................................................................................. Marty McKay

II. Parliamentary Business .............................................................. Marty McKay
   A. Introduction of Members/Roll Call and DHH Staff
   B. Approval of October 31, 2012 Meeting Minutes
   C. Announcement of Election of Officer – Co-Chair

III. P & T Committee Overview ...................................................... Kim Sullivan
   A. P & T Background
   B. P & T Bylaws

IV. Ethics Review ........................................................................... Kim Sullivan

V. Reports ......................................................................................... Melwyn Wendt
   A. Prior Authorization Monthly Report
   B. PDL Reflecting October 31, 2012 P&T Committee Recommendations
   C. Travel Regulations 2013-2014

VI. New Business ............................................................................. Julie Pritchard
   A. Explanation of TOP$, Monographs and Cost Sheets
   B. Therapeutic Class Reviews/Drug Manufacturer Testimony
      1. Alzheimers Agents
      2. Antidepressants, Other
      3. Antidepressants, SSRIs
      4. Antihistamines, Minimally Sedating
      5. Antihypertensives, Sympatholytic
      6. Antihyperuricemics, Oral
      7. Antiparkinsons Agents
      8. Antipsoriatrics, Oral
      9. Antipsoriatrics, Topical
     10. Antipsychotics
     11. Anxiolytics
     12. Bile Salts
     13. Bronchodilators, Beta Agonist
     14. COPD Agents
     15. Cytokine And CAM Antagonists
     16. Emollients
     17. Glucocorticoids, Inhaled
     18. Histamine II Receptor Blockers
     19. Immunomodulators, Atopic Dermatitis
     20. Immunomodulators, Topical
     21. Intranasal Rhinitis Agents
     22. Leukotriene Modifiers
23. Neuropathic Pain  
24. NSAIDs  
25. Ophthalmic Antibiotic/Steroid Combinations  
26. Ophthalmic Antibiotics  
27. Ophthalmics For Allergic Conjunctivitis  
28. Ophthalmics, Anti-Inflammatories  
29. Ophthalmics, Glaucoma Agents  
30. Otic Anti-Infectives  
31. Otic Antibiotics  
32. Sedative Hypnotics  
33. Smoking Cessation  
34. Steroids, Topical - High  
35. Steroids, Topical - Low  
36. Steroids, Topical - Medium  
37. Steroids, Topical – Very High  
38. Stimulants and Related Agents  

VII. New Single Drug Reviews in Current PDL Categories……………………Chris Andrews  
1. Antibiotics Inhaled - Tobi Podhaler  
2. Calcium Channel Blockers - Nymalize  
3. Cephalosporins and Related Antibiotics - Suprax Caps  
4. Antiemetic/Antivertigo Agents - Diclegis  
5. Hypoglycemics, SGLT2 - Invokana  
6. Lipotropics, Other - Kynamro  
7. Lipotropics, Statins - Liptruzet  
8. Multiple Sclerosis Agents - Tecfidera  
9. Ulcerative Colitis Agents - Delzicol  

VIII. Other Business  

VIII. Next Steps  
A. Proposed Therapeutic Classes to be Reviewed at Next Meeting  

IX. Next Meeting Date – April 30, 2014 or May 7, 2014  

X. Public Testimony